Teva Pharmaceutical Industries (TEVA) Other Working Capital Changes (2016 - 2026)

Teva Pharmaceutical Industries has disclosed Other Working Capital Changes across 11 years of filings, most recently posting -$302.0 million for Q1 2026.

• Quarterly Other Working Capital Changes fell 2920.0% year-over-year to -$302.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 310.24% YoY) and the FY2025 annual result came in at $81.0 million, down 85.54% from the prior year.
• Other Working Capital Changes rose to -$302.0 million in Q1 2026, from -$1.5 billion in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $592.0 million in Q2 2024 and troughed at -$1.5 billion in Q4 2025.
• A 5-year average of -$45.1 million and a median of $2.0 million in 2024 frame the typical range for Other Working Capital Changes.
• Biggest YoY gain for Other Working Capital Changes was 27950.0% in 2025; the steepest drop was 3991.89% in 2025.
• Tracing TEVA's Other Working Capital Changes over 5 years: stood at $179.0 million in 2022, then sank by 263.13% to -$292.0 million in 2023, then surged by 87.33% to -$37.0 million in 2024, then tumbled by 3991.89% to -$1.5 billion in 2025, then surged by 80.05% to -$302.0 million in 2026.
• Business Quant data shows TEVA's Other Working Capital Changes at -$302.0 million in Q1 2026, -$1.5 billion in Q4 2025, and $561.0 million in Q3 2025.